Martindale Pharma launches epilepsy treatment Tapclob

Martindale Pharma has announced the launch of Tapclob, a new epilepsy treatment that will be distributed exclusively by Alliance Healthcare in the UK.

The product is the first licensed oral liquid suspension version of the compound clobazam, complementing existing tablet-based formulations to offer a wider range of dosing options.

Advantages of Tapclob include the fact it is easier to administer, particularly among paediatric patients, while it also provides a replacement to prescribing expensive and unlicensed special versions of clobazam oral liquid products.

As such, it will bring benefits for patients and cost-effectiveness advantages for NHS healthcare providers.

Richard de Souza, chief executive officer of Martindale Pharma, said: "More than half a million people in the UK suffer from epilepsy and this new formulation will allow both prescribers and patients to access a safe and cost-effective licensed oral liquid formulation when required."

Earlier this month, the company appointed AAH, Sangers and TPS Healthcare as its new wholesaler partners for the distribution of hospital products.